Glioblastoma (GBM) is the most common aggressive brain tumor in adults. The development of therapy resistance in GBM necessitates the identification of novel biomarkers to guide molecularly targeted treatment strategies. This study aims to identify potential tumor suppressor genes in GBM and to evaluate their potential as therapeutic targets. Genes localized on deletion regions in GBM tumors were selected using the BioMart database. Microarray datasets containing GBM tumor and normal brain tissue samples were analyzed with GEO2R. A protein-protein interaction (PPI) network was constructed for dDEGs on deletion regions using the String database to identify hub genes. The expression and structural changes of hub genes were examined using GEPIA2 and cBioPortal, respectively. GROMACS software was used to perform molecular dynamics (MD) simulations. A total of 1704 dDEGs located within the deletion regions of GBM tumors were identified. Expression levels of 11 hub genes, including subunits of the entire GABA(A) receptor complex, were significantly downregulated in TCGA GBM samples. Additionally, mutations in CACNA1D, GABRA1, and GABRB2 were predicted to disrupt protein structure and function. Meprobamate was selected as the agonist for GABA(A) receptor-related hub genes. MD simulations indicated that meprobamate remained associated with the GABA(A) receptor but exhibited time-dependent repositioning during the later stages of the simulation. CACNA1D, GABRA1, and GABRB2 may have potential tumor-suppressive roles in GBM. In addition, GABA(A) receptors may represent potential molecular targets in GBM, warranting further experimental investigation.

Because there is little published experience with meprobamate during breastfeeding, other agents may be preferred, especially while nursing a newborn or preterm infant, or when other drugs that can cause sedation are used simultaneously. If meprobamate is required by the mother, it is not necessarily a reason to discontinue breastfeeding. Monitor the infant for sedation, poor feeding and poor weight gain.

Ozone-soil aquifer treatment (O3-SAT) could be employed in land-based treatment systems to achieve improved pharmaceutical and personal care products (PPCPs) and pathogen reduction prior to de-facto recharge of aquifers with reclaimed water. A bench-scale demonstration of O3-SAT was investigated utilizing denitrified effluent to assess attenuation of PPCPs, norovirus (NoV), pepper mild mottle virus (PMMoV), bacteriophage MS2, and tomato brown rugose fruit virus (ToBRFV). Ammonification followed by nitrification evidenced the role of microbial degradation in contaminant removal in the soil columns studied. Ozonation was effective for NoV genetic marker oxidation to below detection (> 4 log removal values), while the PPCPs were removed in the soil columns. Indicator viruses demonstrated limited (ToBRFV and MS2) to negligible (PMMoV) oxidation during ozonation; thus, attenuation via microbial degradation and sorption mechanisms during soil treatment was the governing factor for achieving ∼2 log removal values across treatment conditions. PPCP removal efficiency was compound dependent but followed the categories: 1. Effective oxidation and attenuation, 2. Moderate oxidation and attenuation, 3. Recalcitrant to oxidation and attenuation. Ozonation of characteristically recalcitrant compounds such as sulfamethoxazole, meprobamate, N-N-diethyl-m-toluamide and primidone increased the collective O3-SAT removal compared with SAT alone. Desorption of carbamazepine previously adsorbed to below detection was observed, driven by historical concentrations in soil or modifications to the concentration gradient. These results highlight O3-SAT as a promising enhancement for improving robustness of water reuse treatment systems under a range of operational scenarios.

Carisoprodol, a widely prescribed muscle relaxant, is primarily metabolized into its main active metabolites, meprobamate and hydroxy carisoprodol. Despite its frequent use, the pharmacokinetics of carisoprodol have not been extensively studied, with the majority of research focusing on meprobamate. Moreover, even though carisoprodol has a stereogenic center, no chiral separation of carisoprodol has ever been reported in the literature. The present study describes the first enantioseparation of carisoprodol by a heart-cut bidimensional achiral-chiral chromatographic method in reversed-phase mode with a high-resolution mass spectrometry detector. The method was applied to the calculation of the depletion kinetics of the two enantiomers after incubation in rat liver microsomes. The results revealed that hepatic microsomes metabolize one enantiomer at a significantly faster rate than the other. The work provides valuable insights into the underexplored metabolism of carisoprodol, laying the ground for future pharmacological studies on the single enantiomers.

This article describes updates to previously published recommendations for drug testing in drug-impaired driving cases. A survey of drug testing practices in driving under the influence of drug and motor vehicle fatality cases was sent to toxicology laboratories across the USA and Canada. Following the compilation of survey data, a virtual consensus meeting was held where forensic science practitioners and the authors reviewed the survey results and conducted a comprehensive review of the 2021 recommendations using a modified Delphi method. Tier I and Tier II screening and confirmation scope and cutoffs were re-evaluated to update the recommendations. Carisoprodol and meprobamate were moved to the Tier II scope from Tier I; gabapentin was promoted to the Tier I scope from Tier II; screening cutoffs were differentiated for immunoassay versus non-immunoassay (e.g. chromatographic) screening for blood and oral fluid; cross-reactivity screening requirements were removed and clarified with specific cutoff values; several cutoffs for screening and confirmation were increased or removed for blood and oral fluid; urine was removed as a recommended matrix for testing in cases involving suspected drug impairment.

Understanding the metabolic fate of pharmaceutical compounds is critical for assessing drug safety and efficacy. A combination of advanced analytical techniques and in vitro models allows for detailed investigation of biotransformation processes. This study presents an integrated workflow using carisoprodol as a case study to demonstrate the application of modern analytical strategies for metabolic profiling. An analytical platform based on liquid chromatography-high-resolution mass spectrometry (LC-HRMS) was employed, operating in both MS[1] and MS[2] modes to investigate fragmentation behaviour and identify metabolites. Chromatographic separation was performed using a core-shell C18 column under gradient elution. In vitro metabolic stability studies were conducted using rat liver microsomes, and a deuterated analogue was also tested to assist in structural elucidation of hydroxylated metabolites. Additionally, in silico metabolite prediction tools were applied and compared with experimental results. The compound showed slow metabolic degradation (t1/2 = 233.72 ± 3.09 min) and low intrinsic clearance (CLint, in vitro = 5.930 ± 0.078 µL/min/mg). LC-HRMS enabled identification of meprobamate and a hydroxylated derivative as major metabolites. MS/MS analysis of the deuterated metabolite excluded hydroxylation on the n-pentyl chain as reported in the literature, indicating alternative modification sites. In silico predictions correctly identified meprobamate but misassigned hydroxylation positions for the other metabolite. This study highlights the effectiveness of a multi-technique analytical approach for elucidating drug metabolism. The integration of LC-HRMS, isotopic labelling, and computational tools provides a comprehensive platform for metabolic characterization, while emphasizing the necessity of experimental validation in refining in silico predictions.

Pharmaceuticals prevent and treat diseases, yet inappropriate intake can result in harmful effects including mortality. Contaminants have become recurrent public and wildlife health concerns. Bioaccumulation of contaminants can occur throughout trophic levels of the food web. Dolphins are apex predators often used as sentinel species to assess the health of marine ecosystems because their lipid-rich blubber stores contaminants. We used blubber samples collected from live free-swimming and postmortem common bottlenose dolphins (Tursiops truncatus) in the Gulf of Mexico to explore the presence of pharmaceutical contaminants in the marine ecosystem. Targeted analysis of blubber using ultra-performance liquid chromatography coupled with Orbitrap Fusion Tribrid mass spectrometry confirmed the presence of fentanyl, carisoprodol, or meprobamate in 30 of the 89 dolphins assessed. We provide the first detection of human pharmaceuticals stored in live free-swimming marine mammals, with important implications for understanding ecosystem health.

Traditional 95 percent reference intervals (RIs) for urinary metabolic ratios (MRs) are useful for identifying unusually slow or fast metabolism, but these do not account for cytochrome P450 (CYP450)-mediated variability in drug metabolism. In this study, we re-evaluated MR cutoff limits for 18 metabolite-parent drug pairs using genotype-predicted phenotype frequencies reported by Zhu et al. These pairs include dextrorphan/dextromethorphan, oxymorphone/oxycodone, hydromorphone/hydrocodone, O-desmethyltramadol/tramadol, hydromorphone/-morphine, norbuprenorphine/buprenorphine, norfentanyl/-fentanyl, -noroxycodone/-oxycodone, norhydrocodone/hydrocodone, -7-aminoclonazepam/clonazepam, α-hydroxyalprazolam/alprazolam, norquetiapine/quetiapine, meprobamate/carisoprodol, N-desmethyltapentadol/tapentadol, norketamine/ketamine, -2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine/methadone, -desipramine/imipramine, and nortriptyline/amitriptyline. Using a dataset of 2.2 million urine drug testing (UDT) specimens collected from pain management and rehabilitation clinics, we calculated new MR cutoffs that reflect CYP phenotype distributions. CYP2D6-metabolized drug pairs showed consistent upward shifts in both lower and upper limits relative to 95 percent RIs; for example, the -dextrorphan/dextromethorphan lower limit increased from 0.157 to 0.277 and the upper limit from 245.140 to 282.448. CYP2C19-metabolized pairs demonstrated minimal changes to lower limits but marked decreases in upper limits, eg, meprobamate/carisoprodol upper limit decreased from 942.04 to 133.44, consistent with the high prevalence of increased-function alleles. For CYP3A4, CYP2C9, and CYP2B6, only lower thresholds could be derived, reflecting the absence of validated ultrarapid metabolizer categories. Across drug pairs, CYP-specific thresholds reclassified 2.99-27.86 percent of specimens that fell outside the CYP-informed limits. MR-derived phenotype classifications aligned with the phenotype frequencies reported in Zhu et al., indicating that population-level MR distributions reflect known CYP450 genetic variability. Incorporating CYP-specific cutoffs alongside traditional 95 percent RIs may improve identification of expected genetic metabolism, reduce misclassification, and enhance the interpretive accuracy of MR analysis in clinical UDT.

A new accurate, precise thin layer chromatographic (TLC densitometric) approach was developed for the simultaneous analysis of ergotamine tartrate (ERG), phenobarbital sodium (PHEN), caffeine anhydrous (CAF), dipyrone sodium (DIP) and meprobamate (MEP) in their pure form and in their combined formulation; (MIGRANIL tablets). TLC separation depended on using a stationary phase of TLC plates F254 (20 × 10 cm) and using a developing system of ethyl acetate: methanol: n- hexane (8:2:3, by volume) with UV scanning at 254 nm for ERG, PHEN, CAF and DIP. For MEP, detection was done at 560 nm after spraying with 0.3% ethanolic solution of para -dimethylaminobenzaldehyde (PDAB) and heating at 110 ºC for 30 min. Analysis was performed in the concentration intervals of 0.06-2, 0.15-5 µg/band for ERG and PHEN, respectively; while for CAF, DIP and MEP it was done in the ranges of 0.3-9, 0.5-10, 1-100 µg/band, respectively. Moreover, the method was used for the quantitation of the five studied drugs in their unique formulation and the recovery% was calculated and found to be 102.04, 100.73, 100.65, 99.91, 1nd 101.77% for ERG, PHEN, CAF, DIP, and MEP, in order and all these outcomes proved excellent selectivity of the method. Other validation parameters were tested following ICH guidelines. Accuracy ranged from 98.02 to 100.53% while the obtained %RSD of interday day precision ranged from 1.215 to 1.940%. The environmental impact and performance of the method was tested with several tools; Analytical eco-scale, green analytical procedure index (GAPI), Analytical GREEnness Metric Approach (AGREE), Blue applicability grade index (BAGI), and RGB additive color model. Results ensured minimum hazardous effect on health and environment. This is the first analytical approach developed for simultaneous analysis of the quinary mixture which can be easily applied in any analytical laboratory.

If carisoprodol is required by the mother, it is not necessarily a reason to discontinue breastfeeding. Slight sedation has occurred in a breastfed newborn infant who was exposed during pregnancy and lactation; sedation might be more pronounced in newborns who are exposed for the first time during nursing. Other agents may be preferred, especially while nursing a newborn or preterm infant, or when other drugs that can cause sedation are used simultaneously.

Carisoprodol is a centrally acting muscle relaxant used to relieve acute back pain. Due to the risk of dependence and abuse, carisoprodol should only be used for treatment periods of up to two or three weeks. Carisoprodolol is a Schedule IV controlled substance and carisoprodol overdose can lead to CNS respiratory depression, seizures, and death. Carisoprodol is metabolized by CYP2C19 to meprobamate, a sedative used to treat anxiety disorders. In individuals who have little or no CYP2C19 activity (“CYP2C19 poor metabolizers”), standard doses of carisoprodol can lead to a 4-fold increase in exposure to carisoprodol and a concomitant 50% reduced exposure to meprobamate compared to normal metabolizers. Approximately 3‑5% of Caucasians and Africans, and 15‑20% of Asians, are CYP2C19 poor metabolizers (1). The FDA-approved drug label for carisoprodol states that caution should be used when administering carisoprodol to patients with reduced CYP2C19 activity and when co-administering drugs that inhibit or induce CYP2C19 (1). There are no data on the use of carisoprodol in pregnancy, and the efficacy, safety, and pharmacokinetics of carisoprodol have not been established in pediatric patients (less than 16 years of age).

Occasionally, obtaining an adequate or acceptable postmortem blood specimen for drug analysis is not possible due to factors such as decomposition, exsanguination, or embalming. Submandibular salivary gland tissue, one of three major types of salivary gland tissue in the oral cavity of humans, has been reported to be a viable alternative postmortem specimen for toxicological testing. In this study, we evaluated the performance of the Randox Evidence Investigator instrument and Randox DOA (Drugs of Abuse) Ultra Whole Blood Array for the semi-quantitative determination of 21 immunoassays in an alternative matrix, submandibular salivary gland tissue. We analyzed 132 submandibular salivary gland tissue specimens and compared the generated results to concomitantly collected postmortem whole blood specimen results. Oxycodone 2, meprobamate, barbiturate, benzodiazepine assay 1, zolpidem, and buprenorphine all showed perfect agreement (Cohen's kappa score = 1.00) between the submandibular salivary gland tissue results and the postmortem whole blood results; dextromethorphan, fentanyl, benzoylecgonine, methamphetamine, tricyclic antidepressants, oxycodone 1, and opiate showed an almost perfect agreement (Cohen's kappa score = 0.81-0.99); methadone, generic opioids, and amphetamine exhibited substantial agreement (Cohen's kappa score = 0.61-0.80). Tramadol demonstrated fair agreement (Cohen's kappa score = 0.41-0.60). The lowest measure of agreement was observed with cannabinoids, meeting criteria for slight agreement (Cohen's kappa score = 0.01-0.20). An application of the techniques described in this study could be implemented in postmortem toxicology laboratories as well as medical examiners offices to provide preliminary drugs of abuse test results that can be used to direct additional testing. This study highlights the successful integration of a novel specimen matrix and an "off-label" use of an established analytical technique.

When self-administration with counterfeit or mislabeled medicine is suspected, comprehensive laboratory analysis should be preferred over immunoassay screening to avoid false negative results. Carisoprodol, which was formerly a popular muscle relaxant drug in many countries, has reappeared on illegal drug markets, and may cause an itching, purple-colored rash, even after a single dose.